A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.

John D. Powderly,Anthony W. Tolcher,Patricia LoRusso,Martha Elizabeth Blaney,Daniel Dacosta,William R Henner,Michael Anthony McDevitt,Kathy D. Miller,Talia Golan

A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.

2020

John D. Powderly
Anthony W. Tolcher
Patricia LoRusso
Martha Elizabeth Blaney
Daniel Dacosta
William R Henner
Michael Anthony McDevitt
Kathy D. Miller
Talia Golan

TPS3147Background: CD40 is a key costimulatory molecule for both the innate and adaptive immune systems that is essential for T-cell activation and proliferation. OX40 is a costimulatory molecule t...

Keywords:

Pharmacology
CD40
phase i study
in patient
Agonist
Programmed cell death 1
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations